Slide 1: Q2 2025 Results
August 1, 2025 Q2 2025 Results Stephan B. Tanda, Aptar President and CEO Vanessa Kanu, Executive Vice President and CFO
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q2 2025 Financial Highlights
Q2 2025 Financial Highlights Q2 Highlights: 6% Q2 Reported Sales 3% • Each of our segments contributed positively to our second quarter results and each expanded their adjusted EBITDA Q2 Core Sales Growth* margins from the prior year Growth • Our Pharma and Closures segments drove the growth through
Slide 4: Recent Recognitions
Recent Recognitions Our award-winning commitment to sustainability is a competitive advantage that drives impact for our customers TIME CDP CDP EcoVadis Barron’s* Forbes Newsweek ISS ESG USA Today Le Point One of the Climate A Recognized as a Sustainability Rating In the Top 100 One of the In the To
Slide 5: Q2 2025 Product and Technology Highlights
Q2 2025 Product and Technology Highlights Pharma Beauty Closures Lateral Control Bag-on-Valve with Ophthalmic Bio-Based Dual-Chamber Fragrance Pump for Spray Inverted Closure Flip Top System with Pacifica Soft Squeeze Feedstock Nasal Dispensing with Refillable Packaging Pump with Recyclable Closure
Slide 6: Second Quarter 2025 Reported Results
Second Quarter 2025 Reported Results Q2 Reported Sales Q2 Reported EPS (in millions $) $1,200 $1.80 $1.67 6% $966 $1.60 25% $1,000 $910 $1.34 $1.40 $800 $1.20 $1.00 $600 $0.80 $400 $0.60 $0.40 $200 $0.20 $- $- Q2 2024 Q2 2025 Q2 2024 Q2 2025 +3% 23.5% 20.0% +3% Currency Effects Q2 2024 Q2 2025 Core
Slide 7: Second Quarter 2025 Adj. EPS and Adj. EBITDA
Second Quarter 2025 Adj. EPS and Adj. EBITDA Q2 Adjusted EPS* Neutralizing for foreign Q2 Adjusted EBITDA* currency effects and (in millions $) $2.00 $280 $1.80 $1.66 tax, adjusted EPS $1.60 18% would have increased $1.41 $240 13% over the prior $218 $1.40 year quarter 13% $1.20 $200 $193 $1.00 $0.8
Slide 8: Pharma Second Quarter 2025 Results
Pharma Second Quarter 2025 Results Q2 Sales (in millions $) Adjusted EBITDA Margin % Core Sales* Results by Market $500 40% $443 35.4% • Prescription core sales increased 8% $450 $415 34.1% $400 • Consumer Healthcare cores sales Reported 30% decreased 14% $350 7% • Injectables core sales increased 9
Slide 9: Beauty Second Quarter 2025 Results
Beauty Second Quarter 2025 Results Q2 Sales (in millions $) Adjusted EBITDA Margin % Core Sales* by Market $360 16% $335 $321 14.1% $320 13.9% • Fragrance, Facial Skin Care and Color 14% Cosmetics core sales decreased 4% Reported $280 12% • Personal Care core sales increased 11% $240 4% 10% • Home C
Slide 10: Closures Second Quarter 2025 Results
Closures Second Quarter 2025 Results Q2 Sales Adjusted EBITDA Margin % Core Sales* by Market (in millions $) $200 $189 18% 16.9% $180 $174 15.6% • Food core sales increased 13% 16% $160 Reported • Beverage core sales increased 7% 14% $140 8% • Personal Care core sales decreased 4% 12% $120 Core • Ot
Slide 11: Year-to-Date 2025 Reported Results
Year-to-Date 2025 Reported Results YTD Reported Sales YTD Reported EPS (in millions $) $2,500 $3.50 $3.00 10% $2.83 $2,000 $1,826 2% $1,853 $2.57 $2.50 $1,500 $2.00 $1,000 $1.50 $1.00 $500 $0.50 $- $- YTD 2024 YTD 2025 YTD 2024 YTD 2025 0% 22.1% 22.5% +2% Currency Effects YTD 2024 YTD 2025 Core Sale
Slide 12: Year-to-Date 2025 Adj. EPS, Adj. EBITDA and Free Cash Flow
Year-to-Date 2025 Adj. EPS, Adj. EBITDA and Free Cash Flow YTD Adjusted EPS YTD Adjusted EBITDA* Free Cash Flow* (in millions $) $3.50 $500 $2.86 Neutralizing for foreign • $92 million for the first $3.00 $2.64 8% currency effects and $450 $402 six months resulting 8% $2.50 tax for YTD 2024, Adj $40
Slide 13: Outlook
Outlook Outlook Highlights Earnings Per Share • Looking ahead to Q3, we expect a solid quarter with $1.80 continued strength in Pharma, particularly in Injectables, $1.53 – $1.61 EPS for Q3 2025 driven by rising demand for higher value elastomeric $1.60 $1.54 components fueled by growth in biologics
Slide 14: Appendix
Aptar.4 Appendix
Slide 15: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 15
Slide 16: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 16
Slide 17: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data) Further neutralizing for constant tax rate would have a favorable $0.06 impact for the quarter and an unfavorable ~$0.02 impact for the YTD on the prior year adjusted EPS numbers 17
Slide 18: Reconciliation of Adjusted Earnings Per Diluted Share
Three Months Ending September 30, Reconciliation Expected 2025 2024 Income before Income Taxes $ 131,131 of Adjusted Adjustments: Earnings Per Restructuring initiatives Curtailment gain related to restructuring initiatives 3,864 (1,851) Diluted Share Net investment gain (1,043) Transaction costs rel
Slide 19: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 19
Slide 20: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 20
Slide 21: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands, Except Per Share Data) 21
Slide 22: Reconciliation of Adjusted EBIT After Taxes to Net Income
Reconciliation of Adjusted EBIT After Taxes to Net Income (Unaudited) ($ In Thousands) 22
Slide 23: Reconciliation of Capital to Stockholders' Equity
Reconciliation of Capital to Stockholders’ Equity (Unaudited) ($ In Thousands) 23
Slide 24: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 24
Slide 25: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 ($ In Thousands) Net Cash Provided by Operations $ 125,958 $ 143,579 $ 208,700 $ 235,912 Capital Expenditures (63,425) (68,205) (120,287) (143,866
Slide 26: Supplemental Information
Supplemental Information 26
Slide 27: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 27